Tweets
To Pulse or Not to Pulse in ANCA Associated Vasculitis?
New #ACR26 data found no significant remission benefit with pulse steroids, but serious infections were higher (31% vs 14%). Is it time to rethink their use?
Dr. Michael Putman weighs in: https://t.co/b6cJkI2aXc https://t.co/e0yM3mMQmU
Dr. John Cush @RheumNow ( View Tweet )
1 hour 5 minutes ago
Is It Still Inflammation?
A 34 year old female has axSpA. Her CRP is 3, her MRI is quiet, and her BASDAI is 7. She has tried two biologics and is asking about a third. Before we write that prescription, #ACR26 challenges us to ask a different question: is it still inflammation? https://t.co/K4QVBx3cDa
Dr. John Cush @RheumNow ( View Tweet )
2 hours 25 minutes ago
T-Cell Engagers in Autoimmunity: CRS From 12% to 67% Across Six Reports
Six ACR 2026 reports put BCMA, CD19, CD20 and gamma-delta engagers side by side in autoimmune disease. The efficacy signal is consistent. The safety signal depends almost entirely on how the molecule was https://t.co/M1Kkc08VBQ
Dr. John Cush @RheumNow ( View Tweet )
2 hours 26 minutes ago
Best drug first in RA? Dr. Cush makes the case for not holding your best option in reserve.
Listen to the discussion on the RheumNow podcast: https://t.co/OMx5wUu0Et
Subscribe to the podcast for more. https://t.co/9hIOvNlvf6
Dr. John Cush @RheumNow ( View Tweet )
3 hours 24 minutes ago
What do incretins have to do with inflammation?
Hear Dr. Leonard Calabrese’s “How Incretins Quench Inflammation” on Jan 30 at https://t.co/9THCAABeZ0. Kick off 2027 with rheumatology CME Jan 30–31 in Irving, TX, or live online.
Early-bird pricing through Dec 15. https://t.co/dUrUuCz2Oc
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Sjögren’s and SOB? Think About ILD!
While we excitedly await FDA approval of novel immunotherapies, it is worth reminding ourselves that the new drugs will be indicated primarily for patients with active systemic manifestations of SjD that is of at least moderate severity based https://t.co/T51dAyRpcw
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
CD19 CAR-T Relapse: 7 of 50 in Erlangen, Rescued With BCMA
Relapse after CD19 CAR-T was rare in lupus and common in anti-synthetase syndrome and Scl-70 scleroderma. Six of seven relapsing patients were treated with BCMA-directed therapy and responded again. https://t.co/SCD9wZ5DVa
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
GLP-1 Keeps on Working in PsA
Dr. David Liew | Abstract 2942 | ACR 2026
https://t.co/9lzyNq0RyS https://t.co/E7gjUj6Tgx
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
New FDA Approved for Polymyalgia Rheumatica - Secukinumab
The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate a https://t.co/kmgEiZIiFS
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
A Look Ahead: Precision, Safety and Access as Therapies Grow More Complex
ACR Convergence 2026 closed on a high note with the Clinical Year in Preview, a forward-looking session on the final day presented by Alexis Ogdie, MD, MSCE, of the University of Pennsylvania. https://t.co/br5LBqkqeu
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Conducting a CAR-T Trial: A Pediatric Rheumatologist’s Reflections
At #ACR26, a scientific session titled “Program and Ethical Readiness in Pediatric Rheumatology: Building CAR Therapy Pathways for Rare Disease Care” addressed our readiness as a field for CAR-based therapies. https://t.co/qYWKJtTxmZ
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
One dose for every body? Rethinking drug exposure
Dr. Jiha Lee | Size Matters Session | ACR 2026
https://t.co/zodmhAZm1e https://t.co/kkBrQNmwXW
Dr. John Cush @RheumNow ( View Tweet )
3 days ago
Top 6 Practice-Changing Highlights from ACR26
The content at ACR Orlando was vast. We looked at several posters/listened to many talks, and heard from colleagues. So if we missed some great abstracts that will be practice-changing for you, we apologize in advance.
Here is our https://t.co/JmRpPh8Wzi
Dr. John Cush @RheumNow ( View Tweet )
3 days 4 hours ago
Does a Gout Flare Increase Risk of a Cardiovascular Event?
In 2022, Cipolletta and colleagues published a JAMA study showing a temporal association between gout flares and subsequent major adverse cardiovascular events (MACE). This study reported 93% higher odds of MACE in the https://t.co/G91c9oz7tP
Dr. John Cush @RheumNow ( View Tweet )
3 days 5 hours ago
Who benefits from GLP-1s in your rheumatology clinic?
Hear Dr. Catherine Bakewell tackle that question on Jan 30 at https://t.co/9THCAABeZ0. Kick off 2027 with rheumatology CME Jan 30–31 in Irving, TX, or live online.
Early-bird pricing through Dec 15. https://t.co/xjuAWKqAY9 https://t.co/9Nwx85xIb6
Dr. John Cush @RheumNow ( View Tweet )
3 days 7 hours ago
